Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Results available

Effect of Ketamine on Opioid-Induced Hyperalgesia

NCT00833755
Conditions
Pain, Chronic Pain, Hyperalgesia
Interventions
Ketamine, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pain Management
Interventions
Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Loma Linda, California • Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

NCT05907213
Conditions
Pain, Postoperative, Depression, Postpartum
Interventions
Ketamine (Ketalar) Dose Level 1, Ketamine (Ketalar) Dose Level 2, Ketamine (Ketalar) Dose Level 3, Ketamine (Ketalar) Dose Level 4
Drug
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Demoralization
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
Charles S. Grob, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more
Completed Early Phase 1 Interventional Results available

Ketamine Infusion for Social Anxiety Disorder

NCT02083926
Conditions
Social Anxiety Disorder
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Results available

Oral Ketamine for Control of Chronic Pain in Children

NCT01369680
Conditions
Chronic Pain
Interventions
Ketamine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
8 Years to 22 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, New York
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Bipolar Disorder
Interventions
Ketamine hydrochloride injection, Flat tonic water (e.g., Canada Dry Tonic Water)
Drug
Lead sponsor
Juvenile Bipolar Research Foundation
Other
Eligibility
6 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Not Predetermined, Connecticut • Maplewood, New Jersey • Not Predetermined, New Jersey + 1 more
Conditions
Neuropathic Pain, PTSD
Interventions
Ketamine, Magnesium sulfate, Ketamine + Magnesium sulfate
Drug
Lead sponsor
Margaux M. Salas, PhD
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Recruiting Phase 2 Interventional Accepts healthy volunteers

Imaging Depression in Parkinson's Disease

NCT06402955
Conditions
Parkinson's Disease, Major Depressive Disorder
Interventions
11C-UCB-J, ketamine hydrochloride
Radiation · Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut